<DOC>
	<DOCNO>NCT01041677</DOCNO>
	<brief_summary>This study investigate safety 12 week treatment R256918 , obese patient ( JNJ-16269110 R256918 different name molecule ) . The primary objective study investigate mean change Hepatic Triglyceride Content ( HTGC ) , fat content liver , baseline week 6 12 1H-Magnetic Resonance Spectroscopy ( MRS ) , specialize non invasive radiology test . Additional measure include body mass index ( BMI ) , fast glucose , lipid level , blood pressure . Safety assessment perform trial include laboratory test , vital sign measurement , adverse event reporting .</brief_summary>
	<brief_title>A Study Safety R256918 Obese Patients</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , double-blind ( neither physician patient know name assign drug ) , placebo-controlled , parallel-group study 3 treatment arm , consist 27 obese patient . The study include 3 phase - pretreatment , double-blind posttreatment . During pretreatment phase patient undergo general screening assessment eligible , Magnetic Resonance Spectroscopy ( MRS ) screening perform . During double-blind treatment phase patient receive dietary counseling , study medication , urine blood laboratory test , follow MRS examination regular clinic visit symptom assessment . The double blind treatment phase end end-of-treatment early withdrawal visit . A patient withdrawing study prior end 12 week treatment phase attend early withdrawal visit , end-of-treatment visit . This visit include laboratory test follow MRS examination . Post-treatment : A follow-up evaluation occur 14 day end treatment . Study visit schedule occur nearly every 14 day follow baseline visit week 1 . The total study duration approximately 15 week . The study include follow evaluation safety tolerability : mean percent change liver fat content week 6 week 12 end patient participation study , case early withdrawal . Safety evaluation study include monitor adverse event , clinical laboratory test include pregnancy testing , electrocardiogram ( ECGs ) , vital sign measurement ( pulse blood pressure ) , physical examination , patient report assessment GI symptom . Special clinical laboratory safety test assess blood clot coagulation status , essential fatty acid status , lipid-soluble vitamin status : vitamin A , vitamin D , vitamin E , vitamin K , vitamin A/total cholesterol ratio , vitamin E/total cholesterol ratio liver function test . 10 mg capsule , 15 mg capsule , match placebo capsule take orally .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Nutrition Disorders</mesh_term>
	<criteria>Liver fat content ( HTGC ) 3 % 15 % Obese define BMI 30 50 kg/square meter Fasting plasma glucose &lt; 7.0 mmol/liter History Obesity know cause ( eg . Cushings disease ) Diabetes Mellitus Weight reduce diet receive drug treat obesity within 3 month prior screen Significant change smoke habit within 3 month enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Overweight</keyword>
	<keyword>Body Weight</keyword>
	<keyword>Body Size</keyword>
	<keyword>Nutritional Metabolic Diseases</keyword>
</DOC>